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ABSTRACT
Impact Statement: Ultrasound-guided Brachial Plexus Nerve Blocks (BPNBs) using
Ropivacaine and Dexmedetomidine have been proven to shorten the block’s onset, prolong the
duration of action, and enhance the analgesic efficacy.
Background: Ultrasound-guided Brachial Plexus Nerve Blocks (BPNB) are commonly used as
an alternative to general anesthesia. Research suggests that adding Dexmedetomidine 1mcg/kg to
15ml of 0.5% ropivacaine shortens the onset and prolongs the duration of the block.
Methods: A concise search strategy was implemented to identify suitable studies using
Cumulative Index to Nursing and Allied Health (CINAHL) and PUBMED. Eleven articles
remained, of which 6 studies met all the specifics of the literature review objectives. A virtual
educational module was delivered to Florida International University’s alumni CRNAs, along
with a pre and post survey to evaluate gained knowledge.
Results: Of the 8 total participants (N = 8), 50% (n = 4) demonstrated gained knowledge, 25% (n
= 2) had no change, and 25% (n = 2) exhibited a decrease in understanding. The results are
neither favorable nor unfavorable.
Discussion: There was a significant improvement on the likelihood of considering perineural
dexmedetomidine. The small sample size, the project’s cybernetic dependence, and the virtual
aspect of delivery were limitations of this project.
Conclusion: Considering the ambiguity of the results and the project’s limitations, it is
recommended that further research is conducted to educate, guide, and possibly alter current
practice standards.
Keywords: brachial plexus block; supraclavicular; interscalene; infraclavicular; neuraxial
dexmedetomidine; precedex; perineural dexmedetomidine; ropivacaine, regional anesthesia.
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I. INTRODUCTION
Background
The main goal for anesthesia providers is to provide safe and efficacious anesthesia for
patients undergoing surgical procedures with minimal adverse effects during the entire operative
period. Standards of practice guidelines on peripheral nerve blocks have been implemented to
achieve the best patient outcomes and improve the quality of care. As new research unveils,
practitioners have a moral duty to modify their practice for what is shown to work best. Current
practice modalities of patients undergoing upper extremity surgeries with a brachial plexus block
have shown a deficiency in adequately satisfying the pain management needs in the
postoperative surgical period.1

The deficits in clinical practice have redirected clinicians to seek better alternatives that
may enhance patient outcomes and overturn current hospitalization shortfalls. Recent studies
have evaluated the effects of adjunct perineural additives to brachial plexus blocks, such as
dexmedetomidine, opioids, midazolam, magnesium sulfate, dexamethasone, and neostigmine.2
These studies have countified the outcomes of adding these pharmacological adjuncts to the
peripheral nerve blocks, and the addition of dexmedetomidine has been an outlier in enhancing
the efficacy of peripheral nerve blocks.3

Problem Statement

Regional anesthesia has been widely used and accepted in the anesthesia practice as an
alternative to general anesthesia for various surgical procedures, including those involving the
upper extremities. The regional approach can be used as the primary anesthetic for selected cases
and can also be utilized for pain control in the postoperative period and mobility management. It
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is a known alternative or additive to the usage of general anesthesia for surgical procedures and a
method of decreasing opioid use in the post-anesthesia period.4,5

Surgeries involving the upper extremity may be covered by the administration of an
ultrasound-guided brachial plexus nerve block. The brachial plexus is an extensive network of
nerves extending from the neck to the axilla, which innervates the upper extremity. It comprises
ventral rami, nerve trunks, divisions, cords, and terminal branches.6 Brachial plexus blocks are
generally administered using 0.5% ropivacaine, an amide local anesthetic. Local anesthetics
inhibit voltage-gated sodium channels, thus producing a local sensory and motor neural
blockade.6 The local anesthetics used in brachial plexus blocks have been known to provide
adequate procedural anesthesia and some postoperative pain coverage, depending on the
anesthesia provider administering the block. Anesthesia providers must consider various patientspecific circumstances to evaluate the choice in the anesthetic plan. That evaluation may include
the patient's coexisting medical conditions, comfort level, pain tolerance, body habitus, and the
location of the injury or surgical site in question. Compared to general anesthesia, brachial
plexus halts the transmission of nerve signals, thus significantly minimizing the systemic effects
of surgical stimulation and the body's pain response.6

As new research is generated and randomized clinical trials (RCTs) are conducted,
evidence of current practice deficiencies on the onset, duration, and quality of brachial plexus
blocks using 0.5% ropivacaine as the sole agent has emerged.2 The onset and course of action of
local anesthetics have been found to lack rapidity and enough blockage duration to make a
lasting impact on patients in the postoperative period.1 The mean blockade duration of local
anesthetics alone is about 8 hours.7 Patients have still reported pain-related adverse effects, such
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as nausea, vomiting, and sleep disturbance.8 These negative effects of both the pain response and
the usage of general anesthesia have led providers to resort to adjunct pharmacological
interventions in the postoperative period. These medications are often accompanied by multiple
adverse outcomes such as prolonged post-anesthesia care unit times, respiratory depression, and
delayed discharge.8 RCT studies and meta-analysis reviewed and have demonstrated that the
addition of dexmedetomidine to 0.5% ropivacaine has accelerated the onset of action and
prolonged the duration of brachial plexus and has shown to be effective in minimizing reported
pain and enhanced patient satisfaction.1

Scope of the Problem

The administration of brachial plexus blocks has already been implemented for various
surgical procedures involving the upper extremities. These blocks have been shown to provide
surgical anesthesia but fail to sufficiently deliver postoperative pain control and minimize the
associated adverse effects of pain stress in patients following upper extremity procedures.6 The
use of local anesthetics alone, such as Ropivacaine, bupivacaine, levobupivacaine, and lidocaine,
lacks the duration of sensory block needed for optimal pain coverage in the first 24 hours of the
postoperative period. Patients have reported severe pain levels ranging from 4-5 on the pain
scale, overall malaise, and delayed post-anesthesia care unit (PACU) times following surgical
procedures and the administration of a peripheral nerve block (PNB).8 The patients that received
supplemental pharmacological interventions with opioids reported nausea, vomiting, respiratory
depression, constipation, prolonged PACU times, and delayed discharge times.8

Consequences of the Problem
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Brachial plexus nerve blocks for upper surgical procedures are acknowledged as being an
effective anesthesia technique over a general anesthetic approach.6 This methodology improves
the conventional use of anesthetics and diverts patients from experiencing the adverse effects of
general anesthesia.6 Current practice on the use of peripheral nerve blocks has improved
tremendously, but as new research is done, better alternatives have come forth. In today's
practice, the use of local anesthetics alone, such as Ropivacaine, bupivacaine, levobupivacaine,
and lidocaine, have not adequately provided postoperative pain control in patients undergoing
specific upper extremity procedures.8 This insufficiency has led to undesirable clinical patient
outcomes. The patients have reported deleterious postoperative symptoms from both the lack of
pain control and the administration of pharmacological adjuncts.4-6,8 The patient's hospital
experience has been negatively affected and increased consumption of hospital reserves. Patients
with uncontrolled pain postoperatively require additional resources that extend the time in PACU
and prolong hospital discharge, which leads to increased costs of hospitalization. These patients
are also prone to receiving increased nursing care, supplementary medication administration, and
enhanced medical management.8
Knowledge Gaps

The implementation of perineural dexmedetomidine is relatively a new practice study
that is still being widely researched. Dexmedetomidine is a highly selective a2 adrenergic agonist
used in clinical practice to alleviate pain and induce sedation.9 Recent studies have evaluated the
use of dexmedetomidine in adjunct to local anesthetics when administering peripheral nerve
blocks. Substantial evidence has identified that adding dexmedetomidine, about 1mcg per kg has
significantly shortened the onset of action and prolonged the duration of the sensory block, thus
minimizing pain in the postoperative time frame.2 A study performed by Qianchuang showed a
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decrease in reported pain up to 8 hours more postoperatively than patients only receiving local
anesthetics.10 This change in current practice can lead to eliminating or at least decreasing the
adverse outcomes in the postoperative period for patients undergoing surgeries with brachial
plexus blocks.

Proposal Solution
As more research is conducted, standard practice guidelines evolve to provide the utmost
quality of care. This change can be facilitated by educating anesthesia providers with the most
recent evidence on dexmedetomidine as an adjunct to the local anesthetics used in a brachial
plexus block. Clinicians and hospital organizations must improve patient outcomes and minimize
adverse effects during the hospital stay. Clear and concise display of evidence ranging from
improved outcomes, decreased hospitalization cost, and overall enhanced patient experience are
all methods that may generate an impact and lead to systematic procedural change.11
II. SUMMARY OF THE LITERATURE
Rationale
The administration of brachial plexus blocks has already been implemented for various
surgical procedures involving the upper extremities. These blocks have been shown to provide
surgical anesthesia adequately but fail to sufficiently deliver postoperative pain control and
minimize the associated adverse effects of pain stress in patients following upper extremity
procedures.6 The use of local anesthetics alone, such as Ropivacaine, bupivacaine,
levobupivacaine, and lidocaine, lacks the duration of sensory block needed for optimal pain
coverage in the first 24 hours of the postoperative period.6 Patients have reported moderate pain
levels ranging from 4-5 on the pain scale, overall malaise, and delayed post-anesthesia care unit
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(PACU) times following surgical procedures and the administration of a peripheral nerve block
(PNB).8 The patient's hospital experience has been negatively affected and depletes hospital
reserves. Patients with uncontrolled pain postoperatively require additional resources such as
lengthy PACU times and prolonged discharge, which increase the cost of hospitalization. These
patients are also prone to receiving increased nursing care, supplementary medication
administration, and enhanced medical management.8 The cascade of undesirable outcomes
escalates with each intervention required to control postoperative pain. The patients that
received supplemental pharmacological interventions with opioids also reported nausea,
vomiting, respiratory depression, prolonged PACU times, and delayed discharge times.8
Current practice on the use of peripheral nerve blocks has been enhanced tremendously.
Still, as new research is done, better alternatives that improve all sectors of the patient hospital
stay, such as the addition of dexmedetomidine, have come forth. These studies have countified
the outcomes of adding these pharmacological adjuncts to the peripheral nerve blocks, and the
addition of dexmedetomidine has been an outlier in enhancing the efficacy of peripheral nerve
blocks.7
Methodology
Eligibility Criteria
The RCT studies and systematic reviews selected for this literature review underwent a
concise evaluation that included exclusion and inclusion criteria to match the goal and objective
of this review accordingly. The inclusion criteria entailed peer-reviewed studies within the past 5
years, in the English language, with full-text availability. Exclusion criteria included studies that
included subjects under 18 years old, ASA classification above III, the use of any other local
anesthetics other than Ropivacaine, patients with musculoskeletal disorders, patients with
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extremity neuropathy, and patients with preexisting chronic pain modalities. The study focused
on the identifying efficacy of ultrasound-guided brachial plexus blocks with a control group
using Ropivacaine and a study group using dexmedetomidine as an adjunct agent for patients
undergoing upper extremity procedures. All the databases used during the literature review were
acquired using Florida International University's library recourses.
Based on the target clinical question and study objective, the following keywords were
used to identify high-quality RCTs and systematic reviews: "Brachial plexus block,"
"supraclavicular," "interscalene," "infraclavicular," "neuraxial dexmedetomidine," "Precedex,"
"perineural dexmedetomidine," "Ropivacaine,” and "regional anesthesia."
Information Sources
The debases used for this literature review were accessed via Florida International
University's library resources and involved the use of The Cumulative Index to Nursing and
Allied Health Literature (CINAHL) and MEDLINE (ProQuest).
PICO Question
Does the addition of perineural dexmedetomidine to local anesthetics in adult patients
receiving U/S-guided brachial plexus block for elective surgery, compared to adult patients only
receiving the brachial plexus block with local anesthetics, lead to an enhanced block quality in
the intraoperative and postoperative period.
Population (P): Adult patients receiving a U/S-guided brachial plexus block for elective surgery.
Intervention (I): Adding perineural dexmedetomidine as an adjunct agent to Ropivacaine when
administering brachial plexus blocks for upper extremities.
Comparison (C): Compared to patients only receiving Ropivacaine as a sole agent.
Outcomes (O): Analgesic onset, duration, and block efficacy. (Measured in recovery times,
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the patient reported pain postoperatively and usage of additional analgesia)
Time (T): Intraoperative and postoperative period (1 hour postoperative, 2 hours postoperative,
or the entire postoperative period)
Search Strategy
Using the resources available at Florida International University's library databases,
critical terms used in the search for quality substances pertinent to the literature review included:
Brachial plexus block OR supraclavicular OR interscalene block OR infraclavicular OR axillary
AND neuraxial OR perineural AND dexmedetomidine OR precedex AND Ropivacaine. The
search results were later reduced with the inclusion conditions of articles published from 2014 to
the current year and written in English. Journal articles encompassing procedures for cancer
treatment, brachial plexus blocks using the coracoid approach, and articles covering local
anesthetics other than Ropivacaine were excluded. Articles that included neonates, patients under
the age of 18, and ASA classification above III were also excluded from the election process.
A total of 11 articles remained for revision of the abstract and further evaluation. Of the
11 articles, 1 of the articles did not permit full access to the entire study specifics, and 4 articles
included a brachial plexus nerve approach not relevant to the study in question. The final studies
selected consisted of 4 randomized clinical trials and 2 meta-analyses of randomized clinical
trials. The 6 articles left were of the utmost quality of research and met all the specifics of the
literature review objectives.
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AND

Brachial Plexus Block OR
Supraclavicular Block OR
Interscalene Block OR Infraclavicular
Block OR Axillary Block

AND

Neuraxial OR Perineural

AND

Dexmedetomidine OR Precedex

Ropivacaine

Figure 1. Search Keywords
Results
Study Characteristics

The six selected studies were inclusive of all the search criteria, displayed a significant
level of research, and provided high-quality results that added value to this literature review's
conclusions. The final studies selected consisted of four randomized clinical trials and two metaanalyses of randomized clinical trials. Each research study aimed to evaluate and compare the
efficacy of brachial plexus blocks for upper extremity procedures using Ropivacaine as the sole
agent and adding dexmedetomidine in adjunct to Ropivacaine. The four randomized clinical
trials by Koraki,12 Liu,2 Bharti,9 and Hwang13 encompassed appraisal of the onset, duration of
sensory and motor blockade, duration of analgesia, and overall quality of the block.2,9,12,13 The
meta-analysis produced by Vorobeichik et al. 3 evaluated the onset, duration, and quality of
analgesia and the adverse effects associated with adding perineural dexmedetomidine. ElBoghdadly et al.14 conducted a systematic review and meta-analysis to target the clinical
inconsistencies regarding the efficacy of perineural dexmedetomidine in comparison to the
efficacy of perineural clonidine, which is in the same pharmacological class as
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dexmedetomidine. The RCT done by Hwang extended the study to assess the patient's objective
and subjective pain using standardized scales such as The Visual Analog Scale (VAS).13 Hwang
also explored more profound and quantified potential pain markers intraoperatively and in the
postoperative period. These markers included plasma cortisol, IL-6, IL-8, IL-1β, and substance P
levels in the blood.13 All the articles on the respective RCT studies included in this literature
review were marked as a level II on the level of evidence scale. They had evidence from one
well-established and designed RCT using randomly selected participants. The meta-analysis by
Vorobeichik et al.3 was marked as a level I on the level of evidence scale. This meta-analysis
included an appraisal of a total of 32 RCTs. The 4 research articles contributed high-quality
substance and reliable data to complete this literature review.

Results of Individual Studies
In the study by Hwang et al., the authors focused on evaluating one of the most common
brachial plexus blocks performed in the clinical setting: the interscalene block. Their RCT aimed
to compare the effects of administering an interscalene block with dexmedetomidine combined
with Ropivacaine and an interscalene block with Ropivacaine alone. The patient population
selected was patients undergoing arthroscopic rotator cuff repairs. The author's commencing
hypothesis was that dexmedetomidine added to Ropivacaine when administering Interscalene
brachial plexus blocks would enhance the duration of action and analgesic effect when compared
to Ropivacaine alone. They also intended to assess these block’s impact on pain signifiers such
as plasma interleukins, cortisol, and substance-P levels.13 The data retrieved from obtaining these
specific pain markers further enhanced the quality of the study, as it assessed possible pain
outside the objective and subjective realm. This RCT evaluated 50 patients undergoing rotator
cuff repair as an outpatient procedure. Hwang et al. utilized standardized scales such as the
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Visual Analog Scale (VAS) and the Patient Satisfaction Scale (SAT) to properly assess the
effectiveness of both control groups. The division between the control and dexmedetomidine
groups was equal, with each including 25 patients.13 The procedures were evaluated before study
entry, and they ensured that all the arthroscopic procedures were performed by one surgeon,
using a standard accepted method. The block administration technique remained the same
throughout both groups, using ultrasound guidance in the supine position.13 The study
demonstrated no significant difference between the two groups in the operative period.
The participants in group 1, the dexmedetomidine group, showed significantly lower
VAS levels and significantly higher SAT scores at various times evaluated during the study (1, 3
, 6, 12, and 18 hours postoperatively).13 The study's conclusion revealed that ultrasound-guided
interscalene block with Ropivacaine and dexmedetomidine (Group 1) resulted in a lower VAS
score and higher SAT scores in the first 48 hours following shoulder arthroscopy repair. The
study also exposed those patients receiving interscalene block with Ropivacaine and
dexmedetomidine. They displayed lower levels of plasma IL-6 and IL-8 in the first 48 hours of
surgery and the delayed presence of rebound pain.
In the RCT completed by Koraki et al., the authors guided their research to elucidate the
effects of adding dexmedetomidine to Ropivacaine on the onset and duration of the sensory and
motor blockade of the analgesia duration of ultrasound-guided axillary brachial plexus blocks.12
This study included a total of 37 participants who were randomly divided into two groups. Group
RD contained 19 participants that were administered axillary brachial plexus blocks with the use
of 15mL of 0.5% ropivacaine and 1mL of 100mcgs of dexmedetomidine. Group R was
comprised of 18 participants who were administered axillary brachial plexus blocks using 15mL
0.5% ropivacaine and 1mL of normal saline. All participants were scheduled for upper extremity
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surgery, and an anesthesiologist not related to the study utilized an ultrasound-guided
technique.12 The authors focused the analysis on evaluating the duration of both sensory and
motor blockade, as well as the duration of analgesia.
The results of the study revealed significant differences between the two groups. Group
RD containing the patients receiving an axillary brachial plexus block with the use of both
Ropivacaine and dexmedetomidine displayed an increase in the duration of the sensory, motor,
and duration of analgesia when compared to participants in group R.12 The results also
demonstrated a shortened onset of sensory block in group RD, with no significant difference in
the start of motor blockade.12 Some findings unique to this RCT were the adverse effects
experienced by the participants in the dexmedetomidine group that were not reported in the
ropivacaine group. Out of the patients receiving the addition of dexmedetomidine, two patients
were observed to have bradycardic effects, and three displayed hypotension.12 These patients
received the same dose of 1mL 100mcg dexmedetomidine without consideration of patient
specificity. The adverse effects could be caused by an overdose of medication for the patients'
reported weight.
Continuing the randomized controlled study by Liu et al., the authors investigated the
analgesic effects of adding dexmedetomidine to Ropivacaine versus Ropivacaine as the sole
agent when administering a brachial plexus block for patients undergoing upper extremity
surgery.9 A total of 114 participants were selected for this RCT. The participants were all
classified by the American Society of Anesthesiologists (ASA) physical status classification of
ASA I or II. The study primarily assessed the analgesic effects of both groups at baseline, 2, 4, 8,
12, and 24 hours after surgery by utilizing the postoperative Visual Analog Scale (VAS).
Evaluation of intraoperative stability was achieved by recording vital signs such as heart rate
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(HR), mean arterial pressure (MAP), and percentage of blood saturation (SPO2). The participants
were randomly divided into 2 groups of 57 participants, with group 1 being the control group
receiving a brachial plexus block with only 20mL of 0.375% ropivacaine. Group 2 received a
combination of 20mL of 0.375% ropivacaine and 1mL 100mcg of dexmedetomidine.
The study concluded that there was no significant difference in VAS scores between the
dexmedetomidine group and the control group at baseline and at the fourth hour postoperatively.
The participants who received both Ropivacaine and dexmedetomidine presented with a faster
onset of analgesic effects and longer sensory and motor nerve blockade duration.9 The study also
identified a decrease in both HR and MAP and an increase in SPO2 intraoperatively, which the
authors stated to be a favorable outcome. The reduction in HR and MAP was significant but
remained within normal limits.9 A finding specific to this study was the presence of increased
adverse effects such as nausea and lethargy in the patients in the control group only receiving
Ropivacaine.
The additional article being appraised and included in this literature review is a metaanalysis conducted by Vorobeichik et al.3 This meta-analysis was published in 2017 and intended
to reevaluate their previous meta-analysis where it was not recommended to use
dexmedetomidine as an adjunct agent for brachial plexus blocks. The authors structured their
research to evaluate the duration of sensory and motor blockade, time of onset, analgesia
duration, consumption of supplemental analgesic agents, the severity of pain, patient satisfaction,
and the associated side effects with the use of dexmedetomidine.3 The meta-analysis identified
32 clinical trials with a total patient count of 2,007. Out of the actual 2,007 patients reported,
1,026 received dexmedetomidine as an adjunct to local anesthetics, and 986 were part of the
control group. They aimed to quantify their findings by assessing the total time of sensory and
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motor blockade from administration to complete recovery of the blockade. They assessed
postoperative pain by recording the time after completion of the surgical procedure to the first
request for supplemental analgesics. They also evaluated the postoperative VAS scale.
To conclude the meta-analysis, Vorobeichik et al. 3 findings suggest that the addition of
dexmedetomidine to brachial plexus blocks prolonged the duration of sensory block by 46%,
shortened motor block onset time by 39%, prolongs analgesic effects by 60%, reduced analgesic
consumption in the postoperative period by 10.2mg, reduced pain on the VAS scores, and
improved patient satisfaction.3 The study also reported that patients receiving dexmedetomidine
displayed a higher instance of perioperative bradycardia and hypotension, as well as excessive
undesired sedation.3 Overall, the authors reformed their initial meta-analysis findings and
recommended the use of dexmedetomidine as an adjunct agent for brachial plexus blocks with
careful consideration of the side effects listed above.
The contributions made by El-Boghdadly et al.14 were a valuable addition and provided
more profound insight into the topic at hand. El-Boghdadly et al.14 conducted a systematic
review and meta-analysis to target the clinical inconsistencies regarding the efficacy of
perineural dexmedetomidine compared to the effectiveness of perineural clonidine. This metaanalysis acknowledged the lack of clinical research on perineural dexmedetomidine due to the
novelty of the a2 agonist.14 The authors of this systematic review focused on measuring the
sensory and motor blockade, the duration of action, the effect onset, analgesic duration, and the
potential for block complications. The authors underwent vigorous research incorporating
articles from over 12 research databases. The final appraisal consisted of 14 clinical studies
totaling 868 patients.14 The total sample size was equal, with 419 patients receiving perineural
clonidine and 419 patients receiving dexmedetomidine as an adjunct to local anesthetics. The
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study included patients who received various local anesthetics, including 8 studies with
bupivacaine, 4 studies receiving Ropivacaine, and 2 studies receiving levobupivacaine. The dose
of dexmedetomidine and clonidine were equal in all trials except for two studies. One of the
studies used a set of 50mcg of dexmedetomidine and clonidine, while the other trial administered
150mcgs of dexmedetomidine and only 100mcgs of clonidine. The authors gathered all the data
and generated a detailed meta-analysis. 14
The results of the systematic review were listed in a concise report, displaying the study's
findings. Of the 14 studies evaluated, all the studies demonstrated dexmedetomidine superior in
the sensory block duration. The sensory block was prolonged by an estimated 1.2 compared to
the administration of perineural clonidine. Similarly, the study displayed that dexmedetomidine
also extended the effects of motor blockade by 1.2, compared to clonidine. On the topic of onset
of action, El-Boghdadly et al.14 reported that dexmedetomidine hastened the onset of action of
both the sensory and motor block with a ratio of 0.9, in contrast to clonidine. In evaluating the
analgesic outcomes, analgesia was appraised by various modalities, including dynamic pain
scores, analgesic consumption, and overall patient satisfaction. Dexmedetomidine ranked
superior in prolonging the analgesic effects of the block. All the studies gauged in the metaanalysis reported the successful completion of the surgical procedure. The research also exposed
a higher incidence of excessive sedation and transient bradycardia in the Dexmedetomidine
group.
The randomized control trial conducted by Bharti et al.2 was directed to assess the effects
of dexmedetomidine on the onset of action and duration of block and analgesia postoperatively
during supraclavicular brachial plexus block in patients undergoing upper limb surgeries. The
study targeted a total of 60 patients that received supraclavicular brachial plexus blocks for upper

Peña 22
limb surgeries. The selection process included patients ranging from 20 to 40 years of age, all
categorized as ASA I or II. Six of the 60 patients initially admitted to the study were excluded
due to anesthetic preference and early discharge. All the patients were advised of the risks and
received signed consent for the study. The patients were equally divided into two groups. The
control group consisted of 27 patients who received a supraclavicular brachial plexus block with
equal volumes of 0.75% ropivacaine and 2% lidocaine with epinephrine [1:200,000]. The
dexmedetomidine group consisted of 27 patients who received the same block and included
equal volumes of 0.75% ropivacaine and 2% lidocaine with epinephrine [1:200,000], as well as
the addition of 1mcg/kg dexmedetomidine.2 The block modality of both groups was performed in
the same manner using ultrasound guidance. The study listed a maximal volume of 40ml. The
authors aimed to evaluate the hemodynamic stability, onset, and duration of both sensory and
motor blockade, post-operative pain, and adverse side effects.2
Bharti et al. 2 completed the research study and reported the findings concisely, including
the statistical and numerical results. The patients in the dexmedetomidine group experienced
more favorable outcomes in all fields evaluated.2 The onset of the block was significantly
shorter, and the duration of both sensory and motor blockade was extended in the
dexmedetomidine to those from the control group. The analgesic duration in the
dexmedetomidine group was prolonged compared to the control group.2 Patients who received
the perineural dexmedetomidine as an adjunct to local anesthetics experienced analgesia for an
average of 17 hours, whereas the control group's analgesic coverage was 12 hours. The analgesic
effects were also quantified by administering supplemental pain medication and VAS scores.
The patients in the dexmedetomidine group had decreased additional pain medication
administration and lower VAS scores.2 When evaluating advised effects, the dexmedetomidine
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group displayed lower levels of blood pressure and lower heart rates from baseline than the
control group. The decrease in heart rate and blood pressure did not result in hypotension or
bradycardia. The authors concluded that the administration of 1mcg/kg dexmedetomidine
prolongs block duration, speeds the onset, and provides more extended analgesia compared to
patients receiving local anesthetics alone.2
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Author(s)

Purpose

Methodology/

Intervention(s)/ Measures

Sampling/Setting

Primary Results

Relevant Conclusions

Research Design
Hwang et al.

13

2020

The aim of this

Randomized Clinical

Experimental study used

The study was conducted in

The results of the participants in

The participants in group #1

study focused on

Trial (RCT)

subjects and interventions

a single center and included

group 1, the dexmedetomidine group,

receiving ultrasound guided ISB

according to the aim of focus.

subjects undergoing

showed significantly lower VAS

using a mixture of 1 ml (100

The authors ensured the quality

shoulder arthroscopic

levels and significantly higher SAT

mcg) of DEX and 8 ml of 0.75%

dexmedetomidine

of the research by conducting a

rotator cuff repair. The

scores at various times evaluated

ropivacaine demonstrated lower

(DEX) combined

double blind randomized

sample size consisted of 50

during the study (1,3,6,12, and 18h

VAS scores, higher SAT scores,

with interscalene

clinical trial study eliminating

(N = 50) patients with

postoperatively).8 The conclusion of

lower pain related cytokines, and

block (ISB) and

any bias or preferential

rotator cuff tears. 25

the study revealed that ultrasound-

delayed rebound pain.

interscalene block

involvement. They examined

subjects were allocated to

guided interscalene block with both

alone on post-

the effects of dexmedetomidine

group #1 and received

Ropivacaine and dexmedetomidine

operative pain,

(DEX) combined with

ultrasound guided ISB

(Group 1) resulted in a lower VAS

satisfaction, and

interscalene block (ISB) and

using a mixture of 1 ml

score and higher SAT scores in the

pain related

interscalene block alone on

(100 mcg) of DEX and 8

first 48 hours following shoulder

cytokines within the

post-operative pain,

ml of 0.75% ropivacaine.

arthroscopy repair. The study also

first 48 hours after

satisfaction, and pain related

The remaining 25 subjects

exposed those patients receiving

shoulder

cytokines within the first 48

were placed in group #2

interscalene block with both

arthroscopic rotator

hours after shoulder

and underwent ultrasound

cuff repair.13

arthroscopic rotator cuff

guided ISB alone using a

repair.13

mixture of 1 ml of normal

comparing the
effects of

Level 1

saline and 8 ml of
Ropivacaine.13

Ropivacaine and dexmedetomidine,
displayed lower levels of plasma IL-6
and IL-8 in the first 48h of surgery as
well as the delayed presence of
rebound pain.

Koraki et al,12

The aim of the study

Randomized Clinical

Experimental study used

The study consisted for 37

The results of the study were that

The concluding result of the

2018

was to elucidate the

Trial (RCT)

subjects and interventions

subjects who were all ASA

subjects in group RD experienced a

study revealed significant

according to the aim of focus.

status I-II and were

prolonged duration of sensory block

differences between the two

effects of DEX
added to

The authors ensured the quality

scheduled for elective

(U-value =35, p <.001), Prolonged

groups. Group RD containing

Ropivacaine (ROPI)

Level 1

of the research by conducting a

forearm and hand surgery

motor blockage (p = .001), longer

the patients receiving an axillary

on the onset,

double blind randomized

with the use of ultrasound

duration of analgesia (p < .0010)

brachial plexus block with the

duration of motor

clinical trial study eliminating

guided axillary brachial

compared to the subjects in group R.

use of both Ropivacaine and

and sensory

any bias or preferential

plexus block. The subjects

dexmedetomidine displayed an

blockade, and

involvement. They examined

were randomly divided into

increase in the duration of the

duration of

the effects of DEX added to

two main groups. Subjects

sensory, motor, and duration of
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analgesia when

Ropivacaine (ROPI) on the

in Group RD (n = 19)

analgesia when compared to

administering an

onset, duration of motor and

received ultrasound guided

participants in group R.6 The

ultrasound guided

sensory blockade, and duration

axillary brachial plexus

results also demonstrated a

axillary brachial

of analgesia when

block with 15 mL of 0.5%

shortened onset of sensory block

plexus block.12

administering an ultrasound

ropivacaine and 1mL of

in group RD, with no significant

guided axillary brachial plexus

100 mcg of DEX. Patients

difference in the onset of motor

block.12

in group R (n = 18),

blockade.

received ultrasound guided
axillary brachial plexus
block with 15 mL of 0.5%
ropivacaine and 1 mL of
Normal Saline.12
9

Liu et al, 2018

The goal of this

Randomized Clinical

Experimental study used

The study included a total

The study results demonstrated that

The study concluded that the

randomized

Trial (RCT)

subjects and interventions

of 117 patients receiving

onset time for both sensory and motor

participants who received both

according to the aim of focus.

upper limb surgeries under

blockage was significantly faster in

Ropivacaine and

The authors ensured the quality

brachial plexus block

the combination group (8.9 min vs.

dexmedetomidine presented with

analgesic effect of

of the research by conducting a

anesthesia. The patients

12.4 min for sensation blockade; 7.5

a faster onset of analgesic effects

Ropivacaine in

double blind randomized

were randomized into a

min vs. 12.8 min for motor blockade,

and longer duration of both

controlled study
explored the

Level 1

9

combination with

clinical trial study eliminating

control group receiving

P < 0.05 for both comparisons). The

sensory and motor nerve

dexmedetomidine in

any bias or preferential

Ropivacaine alone and a

duration of the blockade in the

blockade.7 The study also

contrast to

involvement. They examined

combination group

combination group was also

identified a decrease in both HR

Ropivacaine alone

the analgesic effect of

receiving Ropivacaine

significantly prolonged (590.2 min vs.

and MAP and an increase in

on brachial plexus

Ropivacaine in combination

combined with

532.1 min, P < 0.05). 9There

block to provide

with dexmedetomidine in

dexmedetomidine.

difference in VAS scores between the

substitute anesthetic

contrast to Ropivacaine alone

two groups immediately and 4 h after

means for upper

on brachial plexus block to

surgery was non-significant. There

limb trauma

provide substitute anesthetic

was a difference in VAS scores

means for upper limb trauma

between the two groups in, 8, 12 and

surgery. The blocking effect on

24 h after surgery, demonstrated to

sensory and motor neurons,

have significantly lower VAS scores

visual analog scale (VAS)

in the combination group than the

score, heart rate (HR), mean

control group (2.4 vs. 3.0 for 8 h; 2.2

arterial pressure (MAP),

vs. 4.2 for 12 h, and 2.1 vs. 5.4 for 24

surgery.

9

SPO2 intraoperatively, which the
authors stated to be a favorable
outcome. 9
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peripheral capillary oxygen

h, respectively, P < 0.05 for all

saturation (SPO2) and adverse

comparisons). There was a statistical

reactions were compared

difference in HR, MAP and SPO2

between the two groups. 9

between the two groups after
anesthesia, the MAP and HR were
significantly lower, and the SPO2 was
significantly higher in the
combination group than the control
group.

Vorobeichik et al,

This meta-analysis

Systematic review and

The authors pursued and

Data was collected from a

To conclude the meta-analysis,

According to the evidence listed

3

was published in

meta-analysis of

identified relevant studies from

total of 2007 patients, that

Vorobeichik et al.3 findings suggested

in the meta-analysis, it is

2017, and it

randomized clinical

electronic databases including

included 1026 in the

that the addition of dexmedetomidine

indicated that perineural

intended to

trials

the US National Library of

dexmedetomidine group

to brachial plexus blocks prolonged

dexmedetomidine significantly

Medicine database, MEDLINE;

and 981 in the Control

the duration of sensory block by 46%,

shortens the onset, increases the

2017

reevaluate their
previous meta-

Level II

the Excerpta Medica database,

group for analysis.

3

shortened motor block onset time by

quality, and prolongs the

analysis where it

EMBASE; the Cochrane

39%, prolonged analgesic effects by

analgesia of brachial plexus

was not

Databases of systematic

60%, reduced analgesic consumption

blocks. Data also demonstrates

recommended to use

reviews; the Cochrane central

in the postoperative period by

that the benefits are associated

dexmedetomidine as

register of controlled clinical

10.2mg, reduced pain on the VAS

with increased risks of motor

an adjunct agent for

trials; Cumulative Index of

scores, and improved patient

block prolongation and transient

3

brachial plexus

Nursing and Allied Health

satisfaction. The study also reported

blocks. The authors

Literature (CINAHL); Scopus;

that patients receiving

structured their

Web of Science; MEDLINE In-

dexmedetomidine displayed a higher

research to evaluate

Process; and other non-indexed

instance of perioperative bradycardia

the duration of

citations.

and hypotension, as well as excessive

sensory and motor
blockade, time of
onset, analgesia
duration,
consumption of
supplemental
analgesic agents, the
severity of pain,

undesired sedation.3

bradycardia and hypotension.
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patient satisfaction,
and the associated
side effects with the
use of
dexmedetomidine. 3
El-Boghdadly et

El-Boghdadly et al14

Systematic review and

The two authors pursued and

The final appraisal

The results of the systematic review

According to the evidence listed

al,14 2017

conducted a

meta-analysis of

identified relevant studies from

consisted of 14 clinical

were listed in a concise report,

in the meta-analysis, it is

systematic review

randomized clinical

electronic databases including

studies, totaling 868

displaying the findings of the study.

indicated that perineural

and meta-analysis to

trials

US National Library of

patients.14 The total sample

In the 14 studies evaluated, all the

dexmedetomidine significantly

Medicine database, MEDLINE;

size was equal with a total

studies demonstrated

shortens the onset, increases the

the Excerpta Medica database,

of 419 patients receiving

dexmedetomidine to be superior in

quality, and prolongs the

regarding the

EMBASE; the Cochrane

perineural clonidine and

the sensory block duration. The

analgesia of brachial plexus

efficacy of

Databases of systematic

419 patients receiving

sensory block was prolonged by an

blocks in comparison with

perineural

reviews; the Cochrane central

dexmedetomidine as an

estimate of 1.2 compared to the

clonidine. Data also

dexmedetomidine in

register of controlled clinical

adjunct to local anesthetics.

administration of perineural clonidine.

demonstrates that the benefits

comparison to the

trials; Cumulative Index of

The study included patients

Similarly, the study displayed that

are associated with increased

efficacy of

Nursing and Allied Health

who received various types

dexmedetomidine also prolonged the

risks of excessive sedation and

perineural clonidine.

Literature (CINAHL); Scopus;

of local anesthetics

effects of motor blockade by 1.2,

transient bradycardia.

Web of Science; MEDLINE In-

including 8 studies with

compared to clonidine. On the topic

Process; and other non-indexed

bupivacaine, 4 studies

of onset of action, El-Boghdadly et

citations.

received Ropivacaine, and

al.14 reported that dexmedetomidine

2 studies received

hastened the onset of action of both

levobupivacaine. The dose

the sensory and motor block with a

of dexmedetomidine and

ratio of 0.9, in contrast to clonidine. in

clonidine were equal in all

evaluating the analgesic outcomes,

trials except for 2 studies.

analgesia was appraised by various

One of the studies used a

modalities including dynamic pain

set 50mcg of both

scores, analgesic consumption, and

dexmedetomidine and

overall patient satisfaction.

clonidine while the other

Dexmedetomidine ranked superior in

trial administered 150mcgs

prolonging the analgesic effects of the

of dexmedetomidine and

block. All the studies gauged in the

only 100mcgs of clonidine.

meta-analysis reported successful

target the clinical
inconsistencies

Level II
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completion of the surgical procedure.
The research also exposed a higher
incidence of excessive sedation and
transient bradycardia in the
Dexmedetomidine group.
2

Bharti et al, 2015

This study was

Randomized Clinical

Experimental study used

The patients were equally

Bharti et al.2 successfully completed

The study concluded that the

designed to assess

Trial (RCT)

subjects and interventions

divided into two groups.

the research study and reported the

participants who received

according to the aim of focus.

The control group consisted

findings in a concise report, including

dexmedetomidine as an adjunct

The authors ensured the quality

if 27 patients who received

the statistical and numerical results.

to local anesthetics presented

on the onset and

of the research by conducting a

a supraclavicular brachial

The patients in the dexmedetomidine

with a faster onset of both

duration of block

blind randomized clinical trial

plexus block with the

group experienced more favorable

sensory and motor blockade,

the effects of
dexmedetomidine

Level 1

2

and postoperative

study eliminating any bias or

inclusion of equal volumes

results in all fields evaluated. The

longer duration of blockade and

analgesia during

preferential involvement. They

of 0.75% ropivacaine and

onset of the block was significantly

analgesia, decreased

supraclavicular

examined the effects of DEX

2% lidocaine with

shorted, and the duration of both

consumption of pharmacological

brachial plexus

added to Ropivacaine (ROPI)

epinephrine [1:200,000].

sensory and motor blockade was

interventions in the post

block in patients

and lidocaine with epinephrine

The dexmedetomidine

extended in the dexmedetomidine to

anesthesia care unit, and

undergoing upper

on the onset, duration of motor

group consisted if 27

those from the control group. The

decreased VAS scores.2 The

limb surgeries.

and sensory blockade, duration

patients who received the

analgesic duration in the

study also identified a decrease

of analgesia, and post-operative

same block and included

dexmedetomidine group was

in both HR and blood pressure

pain control when

equal volumes of 0.75%

prolonged in comparison to the

perioperatively, but did not

2

administering an ultrasound

ropivacaine and 2%

control group. Patients who received

identify hypotension or

guided supraclavicular brachial

lidocaine with epinephrine

the perineural dexmedetomidine as an

bradycardia in either groups.2

plexus block.2

[1:200,000], as well as the

adjunct to local anesthetics

addition of 1mcg/kg

experienced analgesia for an average

dexmedetomidine.2 The

of 17 hours, whereas the control

block modality of both

group's analgesic coverage was 12

groups was performed in

hours. The analgesic effects were also

the same manner using the

quantified by the administration of

guidance of ultrasound. The

supplemental pain medication and

study listed a maximal

VAS scores. The patients in the

volume of 40ml. The

dexmedetomidine group had

author's aimed to evaluate

decreased supplemental pain

the hemodynamic stability,

medication administration, as well as
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onset and duration of both

lower VAS scores.2 When evaluating

sensory and motor

advise effects, the dexmedetomidine

blockade, post-operative

group displayed lower levels of blood

pain, and overall adverse

pressure and lower heart rates from

side effects.2

baseline than the control group. The
decrease in heart rate and blood
pressure did not result in hypotension,
nor bradycardia. The authors
concluded that the administration of
1mcg/kg dexmedetomidine prolongs
block duration, speeds the onset, and
provides longer analgesia, when
compared to patients receiving local
anesthetics alone.2
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Discussion
Summary of the Evidence
The anesthesia profession continues to evolve as new treatment modalities arise and
relevant research data displays more efficacious standards of care. The 4 articles appraised in this
literature review, 3 RCTs and 1 meta-analysis, all aimed their research efforts to evaluate the
effectiveness of perineural dexmedetomidine in combination with Ropivacaine when
administering brachial plexus blocks for surgeries involving the upper extremity.3,9,12-14 The
research articles assessed a variety of standardized factors to quantify the findings in the studies
and meta-analysis. Vigorous protocols, inclusion, and exclusion criteria were followed to ensure
the data's integrity and eliminate factors that might hinder the results, such as clinical bias and
the possibility of human alteration.14 The authors of each study reported both positive and
negative outcomes associated with their research, allowing practitioners and future researchers to
evaluate the data as a whole and conclude new methods of clinical practice.
The content of the research obtained in this literature review confirms the clinical
benefits of adding dexmedetomidine to Ropivacaine when administering brachial plexus blocks.
The consensus of the findings demonstrates that perineural dexmedetomidine expedites the
block's onset of action, prolongs both motor and sensory blockade, elongates the analgesic
effects, decreases the requirement for supplemental analgesics in the postoperative period,
reduces the VAS scores, and increases the patient's overall satisfaction with correlating increase
in SAT scores.3,9,12,13 The study established by Koraki et al. used the same dose of 1mL 100mcg
dexmedetomidine in all the participants; this dose indicated undesirable effects in a total of 5
participants who exhibited hypotension and bradycardia in the perioperative period.12,14 This
finding is important because it recognizes a possible dose-dependent negative outcome, and
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further studies should be implemented to identify the ideal dose range. The author further
detailed that a weight-dependent dose of 1mcg per kg could be a safer alternative and possibly
eliminate the adverse outcomes associated with the administration of perineural
dexmedetomidine.12 In weighing the outcomes and possible side effects, the published authors
favored and recommended the use of dexmedetomidine, regardless of the study's specific
negative findings.
Conclusion

Undoubtedly, the wide use of ultrasound-guided peripheral nerve blocks for surgical
anesthesia and pain management has significantly increased throughout the years.6 Brachial
plexus blocks are considered for various surgical procedures involving the upper extremity and
for diagnostic and pain control.6 Compared to general anesthesia, brachial plexus blocks stop the
transmission of nerve signals, thus significantly minimizing the systemic effects of surgical
stimulation and the body's pain response.6 The reality of the situation is that current studies have
identified significant opportunities in administering brachial plexus blocks.

The review of the literature discussed in this appraisal consists of the latest evidencebased studies that focus on identifying methods of improving the efficacy of brachial plexus
blocks for upper extremity surgeries. The findings are overwhelmingly favorable in supporting
the use of dexmedetomidine as an adjunct agent to Ropivacaine when administering ultrasoundguided brachial plexus blocks. Each study contained randomized subjects in both the variable
and the control group, vigorous protocols were followed to eliminate the chances of bias or
human influence, and special attention was placed on identifying possible study limitations. The
accord of all the studies listed determined that a change in current practice is warranted. The use
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of perineural dexmedetomidine accelerates the onset of the blockade, extends the motor and
sensory block duration, lengthens the effects of analgesia, minimizes the necessity for auxiliary
analgesic pharmacological agents perioperatively, improves experienced postoperative pain as
seen in the decreased VAS scores, and enhances the patient's hospital satisfaction as shown by
higher SAT scores.3,9,12,13 Clinicians now have the support of evidence to implement a new
practice modality that enhances patient outcomes, provides optimal quality of care, decreases
hospital expenses and utilization of resources, and allows for improved overall patient
experience. It is recommended that organizations generate informative material on the subject
and provide educational courses to display the advantages of perineural dexmedetomidine as a
method to generate practice improvement.

III. PURPOSE/ PICO CLINICAL QUESTIONS/OBJECTIVES

Primary DNP Project Goal

The widespread use of ultrasound-guided peripheral nerve blocks for surgical anesthesia
and pain management has progressively amplified.6 Brachial plexus blocks are implemented for
a variety of procedures that involve the upper extremity as well as for pain control.6 It is a
substitute or supplementation to the use of general anesthesia and a method of decreasing opioid
use in the post-anesthesia period.5 Anesthesia providers must evaluate patient-specific
conditions to assess the technique in the anesthetic plan. That evaluation includes the patient's
coexisting medical needs, comfort level, pain tolerance, body habitus, and the location of the
injury or surgical site.6 In contrast to general anesthesia, brachial plexus blocks impede the
transmission of nerve signals, thus significantly diminishing the systemic effects of surgical
stimulation and the physiological response to pain.6
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The local anesthetics used in brachial plexus blocks (BPB) provide adequate procedural
anesthesia, analgesia, and some degree of postoperative pain coverage, depending on the
anesthesia provider administering the block.6 The onset and duration of the block have been
closely monitored and recorded. According to research studies, the onset is not ideal, and the
block duration is not enough to make a lasting impact on patients in the postoperative period.1
Patient has encountered undesirable pain-related effects, such as nausea, vomiting, and sleep
disturbance.8 These adverse outcomes related to pain and the impact of general anesthesia have
prompted the use of adjunct pharmacological interventions in the postoperative period. This use
of pain medications such as oral and intravenous opioids has often been accompanied by
multiple adverse outcomes such as prolonged post-anesthesia care unit times, respiratory
depression, and delayed discharge.8 Current practice modalities of patients undergoing upper
extremity surgeries with ultrasound-guided brachial plexus block have been deficient in
adequately satisfying the pain management needs in the postoperative surgical period.1

The success of BPB is measured by various elements that include the speed of onset,
duration of sensory blockade, duration of analgesia, and overall patient outcome and
satisfaction.2 These blocks have failed to sufficiently deliver postoperative pain control and
moderate the associated harmful effects of pain stress in patients. The use of local anesthetics
alone, such as Ropivacaine, bupivacaine, levobupivacaine, and lidocaine, lacks the duration of
sensory block needed for optimal pain coverage in the first 24 hours of the postoperative period.6
Patients have described severe pain levels ranging from 4-5 on the pain scale, malaise, and
delayed post-anesthesia care unit (PACU) times succeeding surgery with the administration of a
peripheral nerve block.8 The patients receiving supplemental pharmacological interventions with
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opioids have reported nausea, vomiting, respiratory depression, prolonged PACU times, and
delayed discharge times.8

The implementation of perineural dexmedetomidine is relatively a new practice that is
still being widely researched. Dexmedetomidine is a highly selective a2 adrenergic agonist used
in clinical practice to produce analgesia and engender sedation.6 Recent studies have aimed to
evaluate the use of dexmedetomidine as an adjunct to local anesthetics when administering
peripheral nerve blocks. Substantial evidence has identified that adding dexmedetomidine, about
1mcg per kg. has significantly shortened the onset of action and prolonged the duration of the
sensory block, thus reducing pain in the postoperative time frame.2,6 This practice modification
eliminates or at least lessens the adverse outcomes in the postoperative period.

As more research is conducted, standards of practice guidelines evolve to promote the
highest quality of care. The main goal for anesthesia providers is to administer safe and
efficacious anesthesia for patients undergoing surgical procedures with minimal adverse effects
during the entire perioperative period. Current practice guidelines on peripheral nerve blocks
should be reformed to achieve the best patient outcomes and improve the quality of care. This
change can be facilitated by educating anesthesia providers with the most recent evidence on
dexmedetomidine as an adjunct to the local anesthetics used in brachial plexus blocks. Clinicians
and hospital organizations must employ a quality improvement protocol that evaluates and
enhances patient outcomes while decreasing adverse effects during the hospital stay. Clear and
concise display of evidence ranging from improved outcomes, reduced hospitalization cost, and
overall enhanced patient experience are topics of coverage in hospital-wide training that may
generate an impact and lead to systematic procedural change.11
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Objectives
As more research is conducted, standard practice guidelines evolve to provide the utmost
quality of care. This change can be facilitated by educating anesthesia providers with the most
recent evidence on dexmedetomidine as an adjunct to the local anesthetics used in a brachial
plexus block. Clinicians and hospital organizations must improve patient outcomes and minimize
adverse effects during hospital stay. Clear and concise displays of evidence ranging from
improved outcomes, decreased hospitalization cost, and overall enhanced patient experience are
all methods that may generate an impact and lead to systematic procedural change.
IV. DEFINITION OF TERMS
Dexmedetomidine
Selective alpha2-adrenoreceptor agonist with anesthetic and sedative properties due to
activation of G-proteins by Alpha2a- adrenoreceptor in the brainstem, inhibiting norepinephrine
release.12
General Anesthesia
A reversible state of unconsciousness is induced artificially to perform procedures or
surgery. It is apportioned into induction, maintenance, and emergence stages.15
Regional Anesthesia
The use of local anesthetics to block sensations of pain and proprioception from an area
of the body, such as an arm or leg, or the abdomen. Regional anesthesia allows a procedure to be
performed on a region of the body without your need for complete loss of consciousness.15
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Peripheral Nerve Block (PNB):
The injection of local anesthetic near a specific nerve or bundle of nerves to block pain
sensations from the area of the body supplied by the nerve. Nerve blocks are most used for
surgery involving the arms and hands, legs and feet, groin, or face. Peripheral nerve blocks
(PNBs) are used for both surgical anesthesia and as a pain management modality.
V. CONCEPTUAL UNDERPINNING AND THEORETICAL FRAMEWORK OF THE
PROJECT
Theoretical Framework
The project aspires to evaluate, educate, and determine what is needed at a professional
level to introduce a more productive approach to current practice and ultimately improve patient
outcomes. The Donabedian model provides the theoretical framework most consistent with the
project's goals and ambitions. The Donabedian model grants a simple framework for evaluating
care delivery outcomes and consists of three primary concepts: structure, process, and results.16
This theoretical framework allows for evaluating effects by examining the organizational
structure, including available finances, resources, and participants. The administrative process
aspect reviews the current utilization of care and the complete care timeline.16 Conclusively, it
provides an elegant framework for evaluating outcomes and a robust project configuration.
Program Structure
Implementing dexmedetomidine as an adjunct to local anesthetics when conducting an
ultrasound-guided brachial plexus block for upper extremity surgeries will require the
involvement of key stakeholders to allow the passage of modified practice protocols to achieve
improved patient outcomes. The initial phase of the program structure is to conduct a
comprehensive evaluation of current practice modalities and identify protocol opportunities of
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high importance to the stakeholders involved.17 The strength, weakness, opportunities, and
threats (SWOT) analysis tool will be employed to appraise the internal and external
characteristics and threats to the implementation development.
The project's primary goal was to evaluate, educate, and determine what is needed at a
professional level to commence the implementation of perineural dexmedetomidine as an
adjunct to local anesthetics when administering an ultrasound-guided brachial plexus block for
upper extremity surgeries. The initial step was to identify the key stakeholders in the matter and
acquire their involvement to guide the development of a concise educational proposal. The
project participants’ level of knowledge was determined by using a questionnaire developed to
quantify their specific knowledge base on the administration of brachial plexus blocks,
including the time of onset, blockade duration, patient outcomes, and PACU pain coverage,
discharge times, and overall patient satisfaction. The participants then were provided with
educational material illustrating the most current evidence-based research on the use of
perineural dexmedetomidine as an adjunct to local anesthetics when administering an
ultrasound-guided brachial plexus block. The supplemental educational courses would be
conveyed through an academic module. Following the educational intervention, the participants
were asked to complete a questionnaire to determine the knowledge variations before and after
the intervention.
Strengths
The administration of brachial plexus blocks has already been implemented for various
surgical procedures involving the upper extremities. These blocks have been shown to provide
surgical anesthesia adequately. Still, they fail to sufficiently deliver postoperative pain control
and minimize the associated adverse effects of pain stress in patients following upper extremity
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procedure.6 One of the strengths of implementing perineural dexmedetomidine as an adjunct to
brachial plexus blocks for upper extremity procedures would be in line with protocols and
practice modalities already established. This change would modify a regional anesthesia
technique already used in current practice. The material dispersed would allow only a focus on
disclosing current research data, statistical analysis results, and reported patient outcome
advantages. Training on the process, protocol, complications, and patient qualifies for
administering brachial plexus blocks are not subject to change and will remain constant.
Another strength of the project was the alignment with the anesthesia provider's oath to
provide compassionate patient care with seamless coordination and advancing medicine through
unrivaled education, research, and outreach. Unrivaled education signifies providing anesthesia
professionals with the latest quality research and creating a system where education on new
modalities is readily available to all who seek improvement. Therefore, the project's goal was to
allow the CRNA to act on its mission statement and to provide practice modalities that will
deliver high-quality patient care and the best possible outcomes.
Weakness
The project's weaknesses are considered to include any internal traits that can harm the
development and execution of the projected plan.17 These internal barriers can encompass critical
holders such as part-time, full-time, and per-diem certified registered nurse anesthetists. Specific
professional weaknesses identified at an individual practitioner level include variations in
preference of regional anesthesia modality among anesthesia providers, variations in surgeon
preference, perineural dexmedetomidine knowledge deficits among anesthesia providers,
unestablished assigned block personnel schedule, and block time limitation due to fast turnover
expectations.
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Opportunities
The project's professional participation would require the involvement of nurse
anesthesiologists that have direct to adjunct multidisciplinary staff such as anesthesia
technicians, pre-operative registered nurses, operating room registered nurses, and postanesthesia care unit registered nurses and would aid in the project objectives. For the proposed
plan to succeed, all CRNAs sampled should be educated about the changes in practice and the
identification of specific symptoms associated with dexmedetomidine. The scholarly project has
the potential to have a substantial reach in various states and organizational systems. FIU's nurse
anesthesiology program chair facilitated the alumni list with detailed contact information and
board credentials.
Threats
The most present threat to the success of the plan to use dexmedetomidine as an adjunct
to brachial plexus blocks for upper extremity procedures would be denial from critical
stakeholders responsible for the project's approval. Another significant threat was provider
refusal or non-compliance with the expectations of the project. The project had the difficult task
of attempting to change personal practice methodology and encourage experienced anesthesia
providers to modify protocols they have followed during their careers. Change implementation
could generate momentous resistance and thus can lead to an abrupt termination of the project.
Organizational Factors
The plan required the support and alignment of various components, including the
stakeholders, FIU's nurse anesthesiology program chair personnel, and the providers'
willingness. The initial segment in the process would be to determine the steps needed to
generate a perineural dexmedetomidine protocol and usage guidelines. The planning phase also
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encompassed selecting the data that would be included in the educational modules and verifying
the quality and validity of the data being dispersed. During the evaluation phase, anesthesia
providers were interviewed, and feedback on the project's overall effectiveness was obtained.
This process led to the gain of raw data that was later further analyzed and converted into clear
and concise points of value. The analysis included a project narrative, interventions employed,
mission statement, data collection methods, data categorization including modality, analytical
tools used, concise summary of the results, expected and unexpected outcomes, flaws in project
design, and program improvement suggestions.
Goals and Outcomes
The goal of this project was to evaluate current practice protocols, recognize knowledge
gaps, identify personal areas of opportunity, and provide educational material, statistical data,
monetary incentives, and detailed training on the advantages of implementing dexmedetomidine
as an adjunct to local anesthetics when administering an ultrasound-guided brachial plexus
block.
Specific
This educational intervention took place remotely and sample various FIU alumni nurse
anesthesiology providers. Florida International University Alumni Certified Registered Nurse
Anesthetists (CRNA) have direct involvement with the anesthesia management, administration,
and modality selection of ultrasound-guided brachial plexus blocks for upper extremity surgeries.
The sample size indicated the total full-time, part-time, and per-diem CRNAs. The subjects were
chosen from an extensive list of FIU alumni CRNAs provided by FIU's Nurse Anesthesiology
program chair. The sample size included male and female providers of various ages, levels of
education, and ethnic groups.
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Measurable
Evaluation of current knowledge regarding the use of dexmedetomidine for brachial
plexus blocks was obtained before educational intervention. Reassessment was conducted after
completing a concise training module that included educational material, statistical data, hospital
monetary incentives, and detailed training on the advantages of implementing dexmedetomidine
as an adjunct to local anesthetics when administering an ultrasound-guided brachial plexus
block. Outcomes were measured by identifying variations in clinician knowledge on the
advantages and disadvantages of using dexmedetomidine as an adjunct to local anesthetics when
administering an ultrasound-guided brachial plexus block. The reports were generated and
analyzed using Qualtrics®, a standardized survey software.
Achievable
FIU's nurse anesthesiology program chair and part-time, per-diem, and full-time CRNAs
were involved in developing an attainable educational modality.
Realistic
Certified registered nurse anesthetists (CRNAs) in a part-time, full-time, or per-diem role
were evaluated and educated on the most evidence-based research and statistical data available.
Each participant was expected to generate a structured protocol for dexmedetomidine as an
adjunct to local anesthetics when administering an ultrasound-guided brachial plexus block in
their practice.
Timely
The assessment of current knowledge, clinician education, and protocol establishment
would have a projected accomplishment timeframe of 10 months. The outcome of this initiative
was as follows: Within 10 months, anesthesia providers were evaluated and educated on the use
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of dexmedetomidine as an adjunct to local anesthetics when administering an ultrasound-guided
brachial plexus block, and a personal process was implemented where the clinicians can have
access to patient qualifiers, dosages, and contraindications.
VI. METHODOLOGY
Setting and Participants
This educational intervention took place remotely and sample various nurse
anesthesiology providers. The provider samples were Certified Registered Nurse Anesthetists
(CRNAs) alumni of Florida International University's Nurse Anesthesia Program. The nurse
anesthesiology program chair supplied the Provider list.
Description of Approach and Project Procedures
The educational project intervention commenced by inviting FIU alumni Certified
Registered Nurse Anesthetists to participate in the scholarly project. A pretest/posttest was
issued to measure the providers' knowledge of administering brachial plexus blocks and
perineural dexmedetomidine. The data prior to the educational intervention included
demographic information, training level, years of practice, and exposure to regional anesthesia.
During the educational intervention, providers were educated on the project findings and the
patient outcomes when administering brachial plexus block using dexmedetomidine as an
adjunct agent to Ropivacaine. The educational intervention was expected to have a duration of
approximately 15 minutes. Once the interventional education was completed, the participants
were asked to complete a posttest. The findings were then analyzed and quantified.
Protection of Human Subjects
The faculty participants were invited to participate via email notification. Should the
Institutional Review Board (IRB) determine that this study poses more than minimal risk,
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participants consented via Qualtrics, a HIPAA-compliant online survey platform. The
participants completed the scholarly project requirements independently and possessed the
option to opt out. The participant involvement benefits include the refection of current
knowledge, exposure to the latest evidence-based practice, enhancement of their current practice,
and enforcement of expertise to which they might have already been exposed. The data retrieved
was only accessed by the individuals involved in the scholarly project and was password
protected.
Data Collection
Demographic data was collected, including gender, race, ethnicity, and education. Also,
participants were asked to provide the years they have been practicing and whether they have
previously received training on the subject. Previous training on the subject required submission
of the type and length of training. The educational intervention included basic regional
anesthesia questions such as procedural knowledge of brachial plexus blocks, mechanism of
action of local anesthetics including speed of onset and duration of action, mechanism of action
of dexmedetomidine, including speed of onset and course of action. The data was collected via a
HIPAA-compliant online survey platform, Qualtrics.
Data Management and Analysis Plan
The data acquired was stored and analyzed electronically, and only the primary
investigator and participants directly involved in the scholarly project had access to the data. The
identifiers were removed from postings of the finding results; thus, results were anonymous.
Discussion of the Results with Implications for Advanced Nursing Practice
The scholarly project consists of a relatively short educational intervention allowing a
broad reach of FIU alumni CRNAs. The results would provide various positive implications to
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the participants, their organization's current standards of care, and ultimately the patient
outcomes and satisfaction rates. Changes to current practice from the intervention allowed
providers to be educated with the most recent research on brachial plexus blocks using
dexmedetomidine as an adjunct agent to Ropivacaine. It also allowed a chance for the facility to
generate a more efficacious protocol. The intervention has the potential to decrease the patient's
length of stay in the facility, shorten the time in the post-anesthesia care unit, improve postoperative pain control, decrease the amount of supplemental pharmacological administered,
reduce the cost of personnel, mediations, and additional interventions, enhance patient outcomes,
and improve the patient's overall satisfaction.
VII. TIMELINE
Project Timeline
Project Tasks
1. Develop the education intervention.
2. Request FIU Faculty approval.
3. Request FIU's CRNA alumni list.
4. Create and send study invitation.
5. Administer pretest questionnaires.
6. Perform educational intervention.
7. Administer posttest.
8. Analyze the data.
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Figure 2. Project Timeline

VIII. RESULTS
Participant Demographics
Participant demographics are shown in Table 1, and Table 2 displays the participant's
experience.
Table 1. Demographics
Demographics
Total participants

N (%)
8 (100%)

Gender
Male
Female

3 (37.5%)
5 (62.5%)

Ethnicity
African American
Caucasian
Hispanic

1 (12.5 %)
4 (50 %)
3 (37.5 %)

Medical Profession
DNP
8 (100%)
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Table 2. Experience
Experience
Less than one
year
1 to 2 years
2 to 5 years
20+ years

0
5
1
2

The sample size of this survey included a total of 8 participants. A total of 62.5% (n = 5)
of the participants were females and 37.5% (n = 3) were males. The participants in this study
were from assorted ethnic backgrounds, such as African Americans (12.5%), Caucasians (50%),
and Hispanics (37.5%). All participants are CRNAs with Doctoral degrees in Nursing Practice.
The participants were asked about their length of time practicing, which was: those 1 to 2 years
(n = 5, 62.5%), 2 to 5 years (n = 1, 12.5%), and 10 or more years (n = 2, 25%).

Pretest: Assessment of Baseline Knowledge
The pretest was established to determine the clinician's baseline knowledge. The pretest
was delivered before the educational module and the posttest was delivered after the education.
The pretest and posttest consisted of multiple-choice questions and were identical to one another.
The pretest results varied question by question, however none of the participants were able to
achieve perfect scores. Two (25%) participants had the highest scores by answering 90% of the
questions correctly. Overall, the participants scored an average of 71.25% in selecting the correct
response. Results for prettest questions are listed below in Table 3, and outcomes for pretest
question 11 are seen in Figure 3 below.
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Regarding the eleventh question on the Pretest, 2 (25%) answered "somewhat unlikely,"
2 (25%) answered "neither likely nor unlikely," 3 (37.5%) answered "Somewhat likely," and 1
(12.5%) answered "Extremely likely." Results for pretest question eleven are seen in figure 3
below.

Figure 3. Pretest Question 11

Pretest results are displayed below in Table 3.
Table 3. Pretest Results
Participant Number (#)
#1
#2
#3
#4
#5
#6
#7
#8

Correct Answers
8/10
8/10
8/10
9/10
8/10
3/10
9/10
4/10

Score
80%
80%
80%
90%
80%
30%
90%
40%
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Posttest: Assessment of Learning
The posttest was presented after the educational module. It was implemented to evaluate
learning and the probability of clinicians incorporating perineural dexmedetomidine as an
adjunct agent to Ropivacaine when administering brachial plexus blocks. Four (50%)
participants demonstrated improved knowledge on the posttest evaluation and scored perfect
scores. Two (25%) participants scored the same on the Pretest and posttest. Lastly, 2 (25%)
participants displayed a decrease in posttest scores compared to pretest scores. Furthermore, 3
(37.5%) CRNAs claimed that they would be "somewhat likely" to consider implementing
incorporating perineural dexmedetomidine as an adjunct agent to Ropivacaine when
administering brachial plexus blocks, and 5 (62.5%) CRNAs would be "extremely likely" to do
so. Results for posttest questions are listed below in Table 5, and outcomes for posttest question
11 are seen in Figure 4 below.

Posttest results are displayed below in Table 4.
Table 4. Posttest Results
Participant Number (#)
#1
#2
#3
#4
#5
#6
#7
#8

Figure 4. Posttest Question 11

Correct Answers
10/10
10/10
10/10
9/10
10/10
3/10
8/10
3/10

Score
100%
100%
100%
90%
100%
30%
80%
30%
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Table 5. Pretest vs. Posttest Scores
Participant Number (#)
#1
#2
#3
#4
#5
#6
#7
#8

Pretest Score
80%
80%
80%
90%
80%
30%
90%
40%

Posttest Score
100%
100%
100%
90%
100%
30%
80%
30%

Difference
+20%
+20%
+20%
No % Change
+20%
No % Change
-10%
-10%

IX. DISCUSSION
The virtual educational project produced mixed results when evaluating the knowledge
gained after the educational module and significantly positive results when evaluating the
likelihood of considering perineural dexmedetomidine as an adjunct agent to Ropivacaine when
administering brachial plexus blocks. After completing the academic module, 50% of the
participants demonstrated knowledge of perineural dexmedetomidine, 25% of participants did
not have any improvement, and 25% exhibited decreased ability after the educational module.
When evaluating the likelihood of CRNAs to consider perineural dexmedetomidine improved
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significantly with 37.5% CRNAs claiming that they would be "somewhat likely" to consider
perineural dexmedetomidine and 5 (62.5%) CRNAs would be "extremely likely" to do so.
Limitations
The most noticeable limitation of the educational project was the small sample size.
Although email invitations were distributed to 88 FIU alumni, 4 of those emails were returned,
unable to be delivered, and only 8 participated in the survey. Several of the emails provided by
the FIU anesthesia department's chair were FIU emails of graduates that may no longer have
access to the university's email account. Another limitation was the virtual aspect of the project.
Cybernetic communication can be unreliable and challenging for CRNA without many
computers or phone literacy. Email invitations have the potential to be overlooked, and there is
limited control over the participant initiating or even completing the survey.
X. IMPLICATIONS OF ADVANCED PRACTICE NURSING
Future Implications for Practice and Career Development
The extensive literature review has identified that the conjunction of perineural
dexmedetomidine with Ropivacaine when administering brachial plexus blocks results in
favorable outcomes with minimal side effects.1-6,8-10,13 However, implementation in practice has
been restricted due to practitioner limitations and inadequate substantial evidence-based
research.
The educational project implemented by the author of this scholarly paper validated that
anesthesia providers are willing to incorporate new approaches to already established practices.
It also demonstrated that with the proper education, they are likely to modify their clinical
training in pursuit of the most up-to-date, evidence-based practices that lead to the best possible
patient outcomes. It is advisable to continue the research on adding perineural dexmedetomidine
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to Ropivacaine when administering a brachial plexus block. New practice guidelines can lead to
improved outcomes, decreased hospitalization costs, and enhanced patient's surgical experience.
XI. CONCLUSION
Amongst the total number of participants in this educational intervention (n = 8), 50% (n
= 4) demonstrated gained knowledge of perineural dexmedetomidine, 25% (n = 2) showed no
change, and 25% (n = 2) exhibited a decrease in understanding. The results are neither favorable
nor unfavorable. All the participants (n = 8) were willing to consider implementing perineural
dexmedetomidine as an adjunct agent to Ropivacaine when administering brachial plexus blocks.
Considering the ambiguity of the results, it is recommended that further research is developed to
educate, train, and possibly alter current practice standards.
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Appendix B

CONSENT TO PARTICIPATE IN A QUALITY IMPROVEMENT PROJECT
“Improving Clinical Knowledge on the Efficacy of Brachial Plexus Blocks with perineural dexmedetomidine
as an adjunct agent to ropivacaine compared to brachial plexus blocks with ropivacaine as a sole agent: An
Educational Module”

SUMMARY INFORMATION
Things you should know about this study:
•
•
•
•

•
•
•

Purpose: Educational module to improve knowledge in utilizing perineural dexmedetomidine as
an adjunct agent to ropivacaine for brachial plexus blocks.
Procedures: If you choose to participate, you will be asked to complete a pre test watch a voice
PowerPoint and then a post test
Duration: This will take about a total of 20 minutes total.
Risks: The main risk or discomfort from this research is minimal. There will be minimal risks
involved with this project, as would be expected in any type of educational intervention, which
may have included mild emotional stress or mild physical discomfort from sitting on a chair for
an extended period of time, for instance.
Benefits: The main benefit to you from this research is increase the participants knowledge in
utilizing perineural dexmedetomidine as an adjunct agent to ropivacaine for brachial plexus
blocks.
Alternatives: There are no known alternatives available to you other than not taking part in this
study.
Participation: Taking part in this research project is voluntary.

Please carefully read the entire document before agreeing to participate.

PURPOSE OF THE PROJECT
You are being asked to be in a quality improvement project. The goal of this project is to
improve health care provider knowledge on the use of perineural dexmedetomidine as an
adjunct agent to ropivacaine for brachial plexus blocks.
NUMBER OF STUDY PARTICIPANTS: If you decide to be in this study, you will be one of
approximately 10 people in this research study.
DURATION OF THE PROJECT
Your participation will require about 20 minutes of your time. If you decide to participate you will
be 1 of 10 participants.
PROCEDURES
If you agree to be in the project, we will ask you to do the following things:
Page 1 of 3
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If you agree to be in the study, we will ask you to do the following things:
1. Complete an online 10 question pre-test survey via Qualtrics, an Online survey product for which the
URL link is provided
2. Review the educational PowerPoint Module lasting 10 minutes via Qualtrics, an Online survey product
for which the URL link is provided.
3. Complete the online 10 question post-test survey via Qualtrics, an Online survey product for which the
URL link is provided.

RISKS AND/OR DISCOMFORTS
The main risk or discomfort from this research is minimal. There will be minimal risks involved
with this project, as would be expected in any type of educational intervention, which may have
included mild emotional stress or mild physical discomfort from sitting on a chair for an extended
period of time, for instance.
BENEFITS
The following benefits may be associated with your participation in this project: An increased
understanding on perineural dexmedetomidine as an adjunct agent to ropivacaine for brachial
plexus blocks.
The overall objective of the program is to increase the quality of healthcare delivery and improve
healthcare outcomes for our patients.
ALTERNATIVES
There are no known alternatives available to you other than not taking part in this project.
However, if you would like to receive the educational material given to the participants in this
project, it will be provided to you at no cost.
CONFIDENTIALITY
The records of this project will be kept private and will be protected to the fullest extent provided
by law. If, in any sort of report, we might publish, we will not include any information that will
make it possible to identify you as a participant. Records will be stored securely, and only the
project team will have access to the records.
PARTICIPATION: Taking part in this research project is voluntary.
COMPENSATION & COSTS
There is no cost or payment to you for receiving the health education and/or for participating in
this project.
RIGHT TO DECLINE OR WITHDRAW
Your participation in this project is voluntary. You are free to participate in the project or
withdraw your consent at any time during the project. Your withdrawal or lack of participation
will not affect any benefits to which you are otherwise entitled. The investigator reserves the
right to remove you without your consent at such time that they feel it is in the best interest.
RESEARCHER CONTACT INFORMATION
If you have any questions about the purpose, procedures, or any other issues relating to this
research project, you may contact Pedro Pena at 305-833-9130/ ppena025@fiu.edu and Dr.
Yasmine Campbell at 305-348-9894/ ycampbell@fiu.edu
Page 2 of 3
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IRB CONTACT INFORMATION
If you would like to talk with someone about your rights pertaining to being a subject in this
project or about ethical issues with this project, you may contact the FIU Office of Research
Integrity by phone at 305-348-2494 or by email at ori@fiu.edu.
PARTICIPANT AGREEMENT
I have read the information in this consent form and agree to participate in this study. I have had a
chance to ask any questions I have about this study, and they have been answered for me. By
clicking on the “consent to participate” button below I am providing my informed consent.

Page 3 of 3
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Appendix C

Improving Clinical Knowledge on the Efficacy of Brachial Plexus Blocks with perineural
dexmedetomidine as an adjunct agent to ropivacaine compared to brachial plexus blocks
with ropivacaine as a sole agent: An Educational Module
Dear FIU Alumni, Anesthesia Provider:
My name is Pedro Pena, and I am a student from the Anesthesiology Nursing Program
Department of Nurse Anesthetist Practice at Florida International University. I am writing to
invite you to participate in my quality improvement project. The goal of this project is to
improve health care provider knowledge on the use of perineural dexmedetomidine as an adjunct
agent to ropivacaine when administering a brachial plexus block. You are eligible to take part in
this project because you are an alumni CRNA FIU’s DNAP program.
If you decide to participate in this project, you will be asked to complete and sign a consent form
for participation. Next, you will complete a pre-test questionnaire, which is expected to take
approximately 5 minutes. You will then be asked to view an approximately 15 minute long
educational presentation online. After watching the video, you will be asked to complete the
post-test questionnaire, which is expected to take approximately 5 minutes. No compensation
will be provided.
Remember, this is completely voluntary. You can choose to be in the study or not. If you'd like
to participate or have any questions about the study, please email or contact me at
ppena025@fiu.edu or 305-833.9130
Thank you very much.
Sincerely,
Pedro Pena, SRNA, BSN, CCRN

Page 1 of 1
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Appendix D

Name: Pedro Pena

Date: February 5, 2022
Pretest and Posttest Questionnaire:

Improving clinical knowledge on the efficacy of brachial plexus blocks with perineural
dexmedetomidine as an adjunct agent to ropivacaine compared to brachial plexus blocks with
ropivacaine as a sole agent: An Educational Module

INTRODUCTION
The primary aim of this QI project is to educate anesthesia providers on the latest evidenced
research regarding the addition of perineural dexmedetomidine to ropivacaine when
administering brachial plexus blocks for upper extremity surgeries.
Please answer the question below to the best of your ability. The questions are either in
multiple choice or true/false format and are meant to measure knowledge and perceptions on the
use of perineural dexmedetomidine as an adjunct agent to ropivacaine for brachial plexus blocks.

PERSONAL INFORMATION
1. Gender: Male

Female

Other________

Caucasian

African American

2. Age: ______
3. Ethnicity:
Hispanic

Asian

Other_______________

4. Position/Title: _________________________________
5. Level of Education: Certificate Bachelors Masters Doctorate

Other ___________

6. How many years have you been an anesthesia provide?
Over 10

5-10 years

2-5 years
Page 1 of 5
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QUESTIONNAIRE
1. In contrast to a single shot brachial plexus block using ropivacaine as the sole agent,
a single shot brachial plexus block with perineural dexmedetomidine as an adjunct
agent to ropivacaine is associated with of the following laboratory findings:
a. Significantly lower mean plasma cortisol levels 6hrs post-operatively
b. Significantly lower mean plasma substance P levels 1hr post-operatively
c. Significantly lower mean plasma IL-6 level at 1, 6, 12, and 48 h postoperatively
d. All the above
2. Recent data states that the median duration of analgesia of an ultrasound guided
brachial plexus block with the use of 0.5% ropivacaine is:
a. 5 Hours
b. 3.6 Hours
c. 14 Hours
d. 8 Hours
3. [Select Four]. Poorly managed acute post-operative pain can result which negative
outcomes?
a. Prolonged recovery periods
b. Acholuria
c. Impaired immune function
d. Hypoventilation
e. Delayed discharge
f. Sleep Disturbances
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g. Xerostomia
4. Select the correct mechanism of action of Dexmedetomidine?
a. Potent μ-receptor agonist
b. N-Methyl-D-aspartate receptor antagonist
c. Highly selective a2 adrenergic agonist
d. Inhibition of alpha 2 delta subunit of voltage gated calcium channels
5. What recommended dose of perineural dexmedetomidine results in optimal efficacy
while minimizing the risk of adverse side effects?
a. 100mcg-200mcg
b. 25mcg -50mcg
c. 1mcg/kg
d. 4-5mcg/kg
6. According to the latest evidenced based research on perineural Dexmedetomidine,
all the following are expected outcomes, except?
a. Shortened time of onset
b. Prolonged sensory blockade
c. Prolonged motor blockade
d. Prolonged analgesia
e. Shortened motor blockade
7. Upon reviewing the latest evidenced based research on single shot brachial plexus
blocks with 0.5% ropivacaine and 1mcg/kg perineural Dexmedetomidine, the
anesthesia provider displays adequate understanding by selecting which three
potential side effects?
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a. Transient bradycardia
b. Increased MAP
c. Hypertension
d. Hypothermia
e. Hypotension
f. Excessive sedation
g. Transient tachycardia
8. Post-operative pain that requires supplemental pharmacological intervention with
opioids can result is which of the following undesired outcomes?
a. Increased risk to develop PONV
b. Respiratory depression
c. Constipation
d.

Prolonged hospitalization

e. Extended post anesthesia care unit (PACU) time
f. All the above

9. True or False. According to current research, patients receiving a brachial plexus
block with both ropivacaine and perineural dexmedetomidine, displayed lower
levels of plasma IL-6 and IL-8 in the first 48h of surgery as well as the delayed
presence of rebound pain.
a. True
b. False
10. Which perineural dose of dexmedetomidine is associated with an increased risk of
intraoperative hemodynamic instability?
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a. 1mcg/kg
b. 25mcg -50mcg
c. 100mcg-150mcg
d. Perineural dexmedetomidine is not associated with any dose dependent
hemodynamic changes

11. How likely are you to consider perineural dexmedetomidine as an adjunct agent to
ropivacaine when administering a single shot brachial plexus block?
a. Most likely
b. Somewhat likely
c. Somewhat unlikely
d. Most unlikely
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From this quality improvement module, you will:

Improving Clinical Knowledge On The Efficacy Of Brachial
Plexus Blocks With Perineural Dexmedetomidine As An Adjunct
Agent To Ropivacaine Compared To Brachial Plexus Blocks
With Ropivacaine As A Sole Agent: An Educational Module

q Discuss brachial plexus blocks
q Discuss dexmedetomidine
q Understand the effects of postoperative pain on patient outcomes

Nicole Wertheim College of Nursing & Health Sciences, Florida International University
Pedro O. Peña BSN, RN, CCRN

q Identify the impact of pharmacological interventions in the post operative

Yasmine Campbell DNP, CRNA, APRN

period

1

2

E ffe ct s o f in a d e q u a t e p o st - o p e r a t iv e p a in co n t r o l
Brachial plexus block w ith ropivacaine alone
provides analgesia for a m ean duration of 8hrs1

PONV 2
Sleep Disturbance 2

Brachial plexus block with ropivacaine and
perineural dexmedetomidine provides analgesia for
a mean duration of 12hrs1

Prolonged PACU time / Delayed Discharge 2

Impairs immune function3
The use of α2 agonists with local anesthetics has
proven to reduce their overall dosage and thereby
reduce the risk of local anesthetic toxicity1

3

Lower Patient satisfaction (SAT scale) / Increased VAS2
Increased need for supplemental pharmacological
intervention4

4

E ffe ct s o f p o st - o p e ra t iv e O p io id a d m in ist r a t io n

Dexmedetomidine
Opioid induced nausea & vomiting 2

• Dexmedetomidine is a highly selective a 2 adrenergic agonist used in
clinical practice to alleviate pain and induce sedation 5

Respiratory depression 2

Evidence in research
• Ideal perineural dose: 1-2mcg/kg (Dosages above 100mcg have been
shown to cause hemodynamic instability)6
• Significantly lower mean plasma cortisol levels 6hrs postoperatively 3
• Significantly lower mean plasma substance P levels 1hr postoperatively 3
• lower levels of plasma IL-6 and IL-8 in the first 48h of surgery as well
as the delayed presence of rebound pain 3

Prolonged PACU time 2
Supplemental O2 requirements 2
Delayed hospital discharge2
Risk for constipation/ ileus 2

5

6

1
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Study Discussion Points:
According to the latest evidenced-based
research, the im plem entation of 1mcg/kg of
dexmedetomidine to 0.5% ropivacaine when
adm inistering a brachial plexus block results in

Prolongs analgesia
duration 1-8

Shortened onset time 1-8

Decreases visual
Analog scale (VAS)
and Enhances
patient satisfaction
(SAT scale) 1-8

Decreased the need
for supplem ental
pharm acological
interventions in the
PACU 1-6

Extended the duration
of m otor, sensory, and
analgesic blockade 1-8

Hwang et al3

Koraki et al 6

Liu et al5

Vorobeichik et al 4

• The participants in
group #1 receiving
ultrasound guided ISB
using a m ixture of 1 m l
(100 m cg) of DEX and
8 m l of 0.75%
ropivacaine
demonstrated
• Lower VAS scores,
• Higher SAT scores,
• Lower pain related
cytokines
• Delayed rebound pain.

• The concluding result
of the study revealed
significant differences
between the two
groups. Group RD
containing the patients
receiving an axillary
brachial plexus block
with the use of both
ropivacaine and
dexmedetom idine
displayed:
• Increased analgesia,
sensory, and m otor,
duration
• The results also
dem onstrated a
shortened onset of
sensory block
• No significant
difference in the onset
of m otor blockade.

• The study concluded
that the participants
who received both
ropivacaine and
dexm edetom idine
presented with:
• Faster onset of
analgesic effects
• Longer duration of
both sensory and
m otor nerve blockade.
• Decrease in both HR
and M AP and an
increase in SPO2
intraoperatively, which
the authors stated to
be a favorable
outcom e. 10

• According to the
evidence listed in the
m eta-analysis it is
indicated that
perineural
dexmedetom idine
significantly:
• shortens the onset
• Prolongs the analgesic
effects
• Increased risks of
m otor block
prolongation
• Transient bradycardia
and hypotension.

Elim inates the side
effects from the
adm inistration of
opioids 1-8

7

8

Study Discussion Points cont.
Bharti et al7
• The study concluded that the participants who received
dexmedetomidine as an adjunct to local anesthetics presented with:
• Faster onset of both sensory and motor blockade
• Longer duration of blockade and analgesia,
• Decreased consumption of pharmacological interventions in the
post anesthesia care unit,
• Decreased VAS scores.6
• The study also identified a decrease in both HR and blood pressure
perioperatively,
• No hypotension or bradycardia in either groups.6
El-Boghdadly et al8
• According to the evidence listed in the meta-analysis it is indicated
that perineural dexmedetomidine significantly:
• Shortened onset of action
• Increased the analgesic quality
• Prolongs the of brachial plexus blocks in comparison with clonidine.
• Data also demonstrates that the benefits are associated with
increased risks of excessive sedation and transient bradycardia.

9

Dexmedetomidine
possesses unique
properties which render it
suitable enhancements of
brachial plexus blocks

Dexmedetomidine has
decreased the need for
supplemental
pharmacological
interventions in the PACU

Dexmedetomidine is a
highly selective potent α2adrenoceptor agonist
providing sedative,
analgesic, and anxiolytic
properties, with minimal
side effects

Minimal decreases in
MAP, transient
bradycardia, and
excessive sedation have
been noted, without
significant clinical impact

It has been shown to
extended the duration of
motor, sensory, and
analgesic blockade

It has shortened the speed
onset

Enhances patient
satisfaction (SAT scale)

Eliminates the side effects
from the administration of
opioids

10
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BACKGROUND

Improving clinical knowledge on the efficacy of brachial
Plexus Blocks with perineural dexmedetomidine as an
adjunct agent to Ropivacaine compared to brachial
plexus blocks with Ropivacaine as a sole agent: An
educational module

An ultrasound-guided brachial plexus nerve block (BPNB) is
commonly used as an alternative to general anesthesia for patients
undergoing procedures involving the upper extremities.

This regional approach provides anesthesia for the operation and
extends into the postoperative period for pain management.

Pedro O. Peña MSN, RN
Nicole Wertheim College of Nursing & Health Sciences
Florida International University
Dr. Yasmine Campbell DNP, CRNA, APRN

Studies have aimed to assess the efficacy of adding dexmedetomidine
as an adjunct agent to Ropivacaine 0.5% when administering single
shot brachial plexus nerve blocks for upper extremity surgeries.

Dr. Virginia Mae Welch, DNP, CRNA, APRN

1

2

BACKGROUND

SCOPE OF THE PROBLEM

Brachial plexus block with ropivacaine alone
provides analgesia for a mean duration of 8hrs1

Effects of inadequate post-operative pain control
• PONV
• Sleep Disturbance
• Prolonged PACU time / Delayed Discharge
• Impairs immune function
• Lower Patient satisfaction (SAT scale) / Increased VAS
• Increased need for supplemental pharmacological
intervention

Brachial plexus block with ropivacaine and
perineural dexmedetomidine provides
analgesia for a mean duration of 12hrs1
The use of α2 agonists with local anesthetics
has proven to reduce their overall dosage
and thereby reduce the risk of local
anesthetic toxicity1

3

4

SCOPE OF THE PROBLEM

Dexmedetomidine is a highly selective a2 adrenergic
agonist used in clinical practice to alleviate pain and
induce sedation
Ideal perineural dose: 1-2mcg/kg (Dosages above
100mcg have been shown to cause hemodynamic
instability)

Effects o f p o st-o p e ra tive O p io id ad m inistra tio n
•
•
•
•
•
•

5

DEXMEDETOMIDINE

Opioid induced nausea & vomiting
Respiratory depression
Prolonged PACU time
Supplemental O2 requirements
Delayed hospital discharge
Risk for constipation/ ileus

Significantly lower mean plasma cortisol levels 6hrs
post-operatively
Significantly lower mean plasma substance P levels
1hr post-operatively
lower levels of plasma IL-6 and IL-8 in the first 48h of
surgery as well as the delayed presence of rebound
pain

6

1
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PICOT QUESTION

PROJECT PURPOSE

Population

Adult patients receiving a U/S guided brachial plexus block for elective
surgery.

Intervention

The addition of perineural dexmedetomidine

Comparison

Compared to patients only receiving ropivacaine as a sole agent

Outcome

Analgesic onset, duration, and efficacy of block. (Measured in recovery times,
the patient reported pain post-operatively, and usage of additional analgesia)

Time

Intraoperative and postoperative period (1-hour postoperative, 2 hours
postoperative, or the entire postoperative period)

7

To educate anesthesia providers
on the latest evidenced research
regarding the addition of
perineural dexmedetomidine to
ropivacaine when administering
brachial plexus blocks for upper
extremity surgeries.

To enhance overall patient
outcomes and satisfaction by
reducing the negative effects
associated with limited onset
and duration of brachial plexus
blocks using ropivacaine as a
sole agent.

8

Quality Improvement Methodology

Search yielded a total of 11 research articles

SEARCH STRATEGY
Database:

• CINAHL
• EBSCO

Exclusion Criteria
• Studies published
prior to 2014
• Participants < 18y
old
• ASA > III
• Procedures for Tx
of Cancer
• Brachial plexus
blocks using the
coracoid approach

Search Terms
• Brachial Plexus
Block OR
Supraclavicular
Block OR
Interscalene Block
OR Infraclavicular
Block OR Axillary
Block AND
Neuraxial OR
Perineural AND
Dexmedetomidine
OR Precedex AND
Ropivacaine

In c lu s io n C r it e r ia

• Full text
availability

4 research articles were excluded for
encompassing various PNB’s not pertinent to
current project

1 research article was excluded for limited access
to results and study specifics

SEARCH RESULTS

6 research articles met all the specifics of the
literature review objectives and were appraised

• Printed 2014 to
current year

9

10

Quality
Improvement
Methodology

Participants:

A total of 8 CRNAs

M ethods:

Pre-test Survey
Educational Module

Quality Improvement
Results
Demographics

N (%)

Total participants

8 (100% )

Post-test Survey

Data Collection:

Data A nalysis:

11

Quality
Improvement
Methodology

• Printed in
English

Anonymous virtual data
collection via Qualtrics
survey platform

Qualtrics data analytical
software to generate
survey results

DEMOGRAPHICS

E x p e rie n c e

Y rs

Less than one
year

0

1 to 2 years

G ender

5

M ale

3 (37.5% )

Female

5 (62.5% )

2 to 5 years
1
20+ years
2

Ethnicity
African Am erican

1 (12.5 % )

Caucasian

4 (50 % )

Hispanic

3 (37.5 % )

12
M edical Profession
DNP

8 (100%)

2
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QU ALITY IM PR O VEM EN T
RESULTS

Discussion

P artic ip an t N u m b er (#)

P re te st S co re

P o s ttes t S c o re

D iffe re n c e

#1

80%

1 0 0%

+20%

#2

80%

1 0 0%

#3

80%

1 0 0%

+20%

#4

90%

90%

N o % C h a ng e

#5

80%

1 0 0%

+20%

#6

30%

30%

N o % C h a ng e

#7

90%

80%

-1 0%

#8

40%

30%

-1 0%

+20%

13

14

Implication of Advanced Practice Nursing
Project
Limitations

Sample
Size

Virtual
Platform

Cybernetic
Contact

The extensive literature review has identified that the conjunction of perineural
dexmedetom idine with Ropivacaine when administering brachial plexus blocks results in
favorable outcomes with m inim al side effects

Discussion

However, im plem entation in practice has been restricted due to practitioner limitations and
inadequate substantial evidence-based research.

Limitations

It is advisable to continue the research on adding perineural dexm edetom idine to
Ropivacaine when administering a brachial plexus block.

New practice guidelines can lead to im proved outcom es, decreased hospitalization cost,
and enhanced patient's surgical experience.

15

16

Conclusion
Review of
Literature

According to the latest evidenced-based
research, the implementation of 1mcg/kg of
dexmedetomidine to 0.5% ropivacaine when
administering a brachial plexus block results in
Prolongs analgesia
duration

Decreases visual
Analog scale (VAS)
and Enhances
patient satisfaction
(SAT scale)

Decreased the need
for supplemental
pharmacological
interventions in the
PACU

17

Amongst the total number of
participants in this educational
intervention (n=8)

50% (n=4) demonstrated
gained knowledge of
perineural dexmedetomidine
25% (n=2) showed no change
25% (n=2) exhibited a
decrease in understanding.

Shortened onset time
The results are neither favorable nor unfavorable.

Conclusion

Extended the duration
of motor, sensory, and
analgesic blockade

All the participants (n=8) were willing to consider
implementing perineural dexmedetomidine as an adjunct
agent to Ropivacaine when administering brachial
plexus blocks.

Eliminates the side
effects from the
administration of
opioids

Considering the ambiguity of the results, it is
recommended that further research is developed to
educate, train, and possibly alter current practice
standards.

18
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